Topcon
7732
TEMONA
3985
Forside
2330
Okamoto Glass
7746
Delta-Fly Pharma
4598
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -3.24%40.34B | 17.33%157.8B | 23.44%41.36B | 11.81%38.41B | 10.38%36.46B | 24.06%41.7B | -0.84%134.5B | -4.10%33.51B | -2.20%34.35B | -0.06%33.03B |
Cost of revenue | 2.17%17.65B | 6.25%71.79B | 17.00%20.24B | 0.88%17.12B | 2.27%17.28B | 5.29%17.27B | 6.85%67.56B | -2.06%17.3B | 10.23%16.97B | 7.84%16.89B |
Gross profit | -7.07%22.7B | 28.51%86.02B | 30.31%21.13B | 22.47%21.29B | 18.87%19.18B | 41.96%24.42B | -7.56%66.93B | -6.19%16.21B | -11.90%17.38B | -7.17%16.13B |
Operating expense | ||||||||||
Operating profit | -7.07%22.7B | 28.51%86.02B | 30.31%21.13B | 22.47%21.29B | 18.87%19.18B | 41.96%24.42B | -7.56%66.93B | -6.19%16.21B | -11.90%17.38B | -7.17%16.13B |
Net non-operating interest income (expenses) | -90.00%3M | 17.02%-39M | -10.53%-21M | -8.70%-25M | -27.78%-23M | 130.77%30M | -4.44%-47M | -26.67%-19M | 0.00%-23M | 5.26%-18M |
Non-operating interest income | -35.71%36M | 40.82%69M | 16.67%7M | 0.00%1M | -20.00%4M | 55.56%56M | -15.52%49M | -45.45%6M | -66.67%1M | -16.67%5M |
Non-operating interest expense | 26.92%33M | 12.50%108M | 12.00%28M | 8.33%26M | 17.39%27M | 13.04%26M | -6.80%96M | -3.85%25M | -7.69%24M | -8.00%23M |
Net investment income | ||||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | -3.26%594M | 8.19%1.43B | 0.00%277M | 0.00%254M | 29.95%282M | 7.53%614M | 23.62%1.32B | 22.57%277M | 37.30%254M | 3.33%217M |
Special income (charges) | ||||||||||
Other non-operating income (expenses) | ||||||||||
Income before tax | -7.08%23.29B | 28.15%87.4B | 29.80%21.38B | 22.16%21.52B | 19.01%19.44B | 40.91%25.07B | -7.11%68.21B | -5.84%16.47B | -11.45%17.61B | -7.06%16.33B |
Income tax | 1.58%7.13B | 21.27%25.45B | 35.21%6.96B | 11.76%6.03B | 8.88%5.44B | 28.90%7.02B | -7.13%20.99B | -5.94%5.15B | -11.44%5.39B | -1.59%5B |
Net income | -10.45%16.16B | 31.20%61.95B | 27.36%14.42B | 26.76%15.49B | 23.49%13.99B | 46.22%18.05B | -7.10%47.22B | -5.80%11.33B | -11.46%12.22B | -9.29%11.33B |
Net income continuous operations | -10.45%16.16B | 31.20%61.95B | 27.35%14.42B | 26.75%15.49B | 23.48%13.99B | 46.21%18.05B | -7.10%47.22B | -5.80%11.33B | -11.45%12.22B | -9.28%11.33B |
Noncontrolling interests | 26.45%392M | 29.11%1.13B | 22.29%192M | 41.45%331M | 28.14%296M | 22.53%310M | 0.23%876M | 98.73%157M | -33.52%234M | 6.45%231M |
Net income attributable to the company | -11.10%15.77B | 31.25%60.82B | 27.44%14.23B | 26.46%15.16B | 23.40%13.7B | 46.71%17.74B | -7.23%46.34B | -6.49%11.17B | -10.87%11.99B | -9.57%11.1B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -11.10%15.77B | 31.25%60.82B | 27.44%14.23B | 26.46%15.16B | 23.40%13.7B | 46.71%17.74B | -7.23%46.34B | -6.49%11.17B | -10.87%11.99B | -9.57%11.1B |
Gross dividend payment | ||||||||||
Basic earnings per share | -11.06%15.155 | 32.78%58.445 | 28.58%13.675 | 27.99%14.565 | 24.92%13.16 | 48.63%17.04 | -6.70%44.015 | -6.05%10.635 | -10.71%11.38 | -9.18%10.535 |
Diluted earnings per share | -11.06%15.155 | 32.78%58.445 | 28.58%13.675 | 27.99%14.565 | 24.92%13.16 | 48.63%17.04 | -6.70%44.015 | -6.04%10.635 | -10.71%11.38 | -9.18%10.535 |
Dividend per share | 0 | 33.96%35.5 | 48.15%20 | 0 | 19.23%15.5 | 0 | -7.02%26.5 | -12.90%13.5 | 0 | 0.00%13 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |